US Patent

US11497718 — Use of tapinarof for the treatment of atopic dermatitis

Method of Use · Assigned to Dermavant Sciences GmbH · Expires 2039-11-13 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of tapinarof for treating mild to moderate atopic dermatitis.

USPTO Abstract

Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3.

Drugs covered by this patent

tapinarof (TAPINAROF)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4048`	—	tapinarof

Patent Metadata

Patent number: US11497718
Jurisdiction: US
Classification: Method of Use
Expires: 2039-11-13
Drug substance claim: No
Drug product claim: No
Assignee: Dermavant Sciences GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.